Advertisement

Immune System–Boosting Agent May Reduce Early-Stage Melanoma Recurrences

Advertisement

Key Points

  • Injections of either CpG-B or placebo were administered directly adjacent to the site of surgical excision of the primary melanoma tumor, 7 and 2 days before reexcision and sentinel lymph node biopsy.
  • After a median follow-up of 76.5 months, 2 of the 30 patients assigned CpG-B and 9 of the 22 patients assigned placebo had experienced melanoma recurrence.
  • Combined results and low patient enrollment may warrant a larger phase III trial to confirm these study results. 

Among patients with clinically stage I or stage II melanoma, those treated with the immune system–boosting agent CpG-B were less likely to experience recurrence of their disease than those who received placebo, according to results from two randomized, placebo-controlled phase II clinical trials presented at the CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference (Abstract A050), held September 16–19 in New York.

“Even though stage 1 and stage 2 melanomas can be removed surgically, in a considerable proportion of patients, cells from the tumor have already spread and eventually lead to tumor recurrence,” said Tanja D. de Gruijl, PhD, Professor and Head of the Immunotherapy Laboratory in the Department of Medical Oncology at the VU University Medical Center Cancer Center Amsterdam. “We set out to investigate whether intradermal injection of the immune-stimulatory compound CpG-B around the site of surgical removal of the primary tumor could boost patients’ antimelanoma immune responses and provide local and systemic protection against early metastatic events that could otherwise lead to tumor recurrence.”

“We found that there was a significant prolongation of recurrence-free survival among the patients who had received CpG-B compared with the patients who received saline placebo,” continued Dr. de Gruijl. “The apparent clinical effect was much stronger than we had anticipated and underlines the powerful ability of the immune system, provided it is properly activated, to control melanoma.”

Study Details

CpG-B is a reagent that closely resembles a stretch of bacterial DNA, explained Dr. de Gruijl. It is perceived by the human immune system as a sign of danger that calls for an immune response.

From 2004 to 2007, Dr. de Gruijl and colleagues enrolled 52 patients with stage I or stage II melanoma in the two clinical trials. Patients were assigned intradermal injection of either CpG-B or saline. Injections were administered directly adjacent to the site of surgical excision of the primary melanoma tumor, 7 and 2 days before reexcision and sentinel lymph node biopsy, which Dr. de Gruijl explained is part of the standard of care at VU University Medical Center Cancer Center Amsterdam.

The researchers found that after a median follow-up of 76.5 months, 2 of the 30 patients assigned CpG-B and 9 of the 22 patients assigned placebo had experienced melanoma recurrence.

Plans for Future Research

“Our results imply that local conditioning of the melanoma excision site by simple intradermal administration of an immune-stimulatory compound like CpG-B can lead to boosting of a systemic antimelanoma immune response that affords protection against recurrences in the long term, with minimal transient side effects,” said Dr. de Gruijl. “We plan to conduct a large, randomized phase III clinical trial of intradermal CpG-B vs saline to confirm our findings of prolonged long-term recurrence-free survival.”

According to Dr. de Gruijl, the major limitations of the study are that the data are the combined results of two phase II clinical trials with low numbers of enrolled patients and that different CpG-B doses were used in the two clinical trials. The low patient numbers mean that a large, randomized phase III clinical trial is needed to confirm the current promising findings, she added.

This study was supported by the Fritz Ahlqvist Foundation. Pfizer provided the CpG-B for the clinical trial. Dr. De Gruijl reported no potential conflicts of interest. 

The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.


Advertisement

Advertisement



Advertisement